ChromaDex (CDXC)
(Delayed Data from NSDQ)
$2.88 USD
+0.25 (9.51%)
Updated Aug 8, 2024 03:59 PM ET
After-Market: $2.86 -0.02 (-0.69%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CDXC 2.88 +0.25(9.51%)
Will CDXC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CDXC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDXC
ChromaDex (CDXC) Reports Break-Even Earnings for Q2
Regeneron (REGN) Surpasses Q2 Earnings and Revenue Estimates
CDXC: What are Zacks experts saying now?
Zacks Private Portfolio Services
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates
Other News for CDXC
Roth MKM Remains a Buy on Chromadex (CDXC)
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
ChromaDex Corporation 2024 Q2 - Results - Earnings Call Presentation
ChromaDex: Q2 Earnings Snapshot
ChromaDex Corporation Reports Second Quarter 2024 Financial Results